←
Breno Moreno de Gusmão1,398 posts
Breno Moreno de Gusmão avatar

Breno Moreno de Gusmão

@morenodegusmao

Hematologist | BP São Paulo, Brazil Myeloma · Amyloidosis · Cell Therapy · Clinical Research Sharing data that matters

◷ Joined March 2013▧ 244 Photos and videos
Breno Moreno de Gusmão avatar
Breno Moreno de Gusmão@morenodegusmao·17h

Quad-class exposed RRMM in real life (Flatiron, n=241 starting next therapy, median 5 prior lines): median EFS 5.0 mo, OS 15.6 mo. ~25% died before each subsequent line. GPRC5D bispecifics were the most used next option. #mmsm doi.org/10.1182/bloodadvance…

Breno Moreno de Gusmão avatar
Breno Moreno de Gusmão@morenodegusmao·17h

FORTE long-term (median FU 99 mo): KRd-ASCT beat KRd12 for PFS (median 98 vs 70 mo; HR 0.71) and KCd-ASCT for OS (8-yr 76% vs 68%; HR 0.65). Carfilzomib + lenalidomide maintenance improved PFS vs R (HR 0.67), no OS gain. #mmsm doi.org/10.1182/blood.202603…

Breno Moreno de Gusmão avatar
Breno Moreno de Gusmão@morenodegusmao·Nov 16

BCMA bispecifics in R/R AL at #ISA2026: elranatamab (phase I/II, n=11) and teclistamab (real-world, n=52). Fast, deep responses, no ICANS. Infection is the key risk: sepsis deaths 3/42 with IVIG vs 5/8 without. Very different populations (Mayo IIIB 0% vs 25%). #mmsm

Post attachment
Breno Moreno de Gusmão avatar
Breno Moreno de Gusmão@morenodegusmao·Nov 16

#ISA2026: Dr. Eli Muchtar (Mayo) on ALERT, an ML model to flag AL among MGUS/SMM (n=7,818). With sFLC, AUC 0.94. AI-ECG helps most without sFLC (0.85 to 0.94). At PPV 10%, AI-ECG raised sensitivity from 50% to 75%. Prospective testing next. #mmsm

Post attachmentPost attachmentPost attachmentPost attachment
Breno Moreno de Gusmão avatar
Breno Moreno de Gusmão@morenodegusmao·Nov 15

The ATTR landscape is moving fast at #ISA2026 (Drs. Prem Soman and Marcia Waddington). Every step is now a target: gene editing (nex-z), silencers (vutrisiran, patisiran, eplontersen), stabilizers (tafamidis, acoramidis), fibril depleters (ALXN2220, coramitug, AT-02). #mmsm

Post attachmentPost attachment
Breno Moreno de Gusmão avatar
Breno Moreno de Gusmão@morenodegusmao·Nov 15

3/3 Typing: laser microdissection + mass spectrometry is the gold standard; IHC can misclassify. Scans fail too: blood pool, low-avidity TTR variants, AL uptake. Monoclonal protein or discordant data = biopsy and type. #ISA2026 #mmsm

Breno Moreno de Gusmão avatar
Breno Moreno de Gusmão@morenodegusmao·Nov 15

2/3 Yield by site (as presented): fat pad AL ~84%, ATTRv ~45%, ATTRwt ~15%; minor salivary gland AL ~81-89%; bone marrow AL ~55%, ATTR ~30%. The involved organ has the highest yield. Congo red reading needs expertise. #ISA2026 #mmsm